Clark Capital Management Group’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$103M Sell
474,417
-128,376
-21% -$28.5M 0.64% 33
2025
Q4
$138M Sell
602,793
-92,598
-13% -$21.1M 0.85% 25
2025
Q3
$161M Buy
695,391
+90,508
+15% +$18.4M 1.01% 15
2025
Q2
$112M Buy
604,883
+33,163
+6% +$6.16M 0.78% 28
2025
Q1
$120M Buy
571,720
+567,818
+14,552% +$110M 0.86% 22
2024
Q4
$693K Buy
3,902
+173
+5% +$31.8K ﹤0.01% 319
2024
Q3
$736K Sell
3,729
-4,441
-54% -$829K 0.01% 313
2024
Q2
$1.4M Buy
8,170
+3,263
+66% +$541K 0.01% 258
2024
Q1
$894K Sell
4,907
-637
-11% -$110K 0.01% 291
2023
Q4
$859K Sell
5,544
-5,345
-49% -$779K 0.01% 284
2023
Q3
$1.62M Buy
10,889
+197
+2% +$28.9K 0.02% 232
2023
Q2
$1.44M Sell
10,692
-825
-7% -$121K 0.01% 241
2023
Q1
$1.84M Sell
11,517
-280,334
-96% -$42.9M 0.02% 217
2022
Q4
$47.2M Buy
291,851
+10,257
+4% +$1.57M 0.43% 53
2022
Q3
$37.8M Buy
281,594
+10,897
+4% +$1.56M 0.5% 49
2022
Q2
$41.5M Sell
270,697
-108,981
-29% -$16.7M 0.54% 43
2022
Q1
$61.5M Buy
379,678
+9,742
+3% +$1.42M 0.69% 28
2021
Q4
$50.1M Buy
369,936
+5,705
+2% +$674K 0.61% 41
2021
Q3
$39.3M Buy
364,231
+120,309
+49% +$13.7M 0.54% 54
2021
Q2
$27.5M Buy
243,922
+227,236
+1,362% +$25.6M 0.39% 101
2021
Q1
$1.81M Sell
16,686
-2,790
-14% -$298K 0.03% 224
2020
Q4
$2.09M Sell
19,476
-4,231
-18% -$407K 0.03% 224
2020
Q3
$2.08M Buy
23,707
+93
+0.4% +$8.76K 0.04% 212
2020
Q2
$2.32M Buy
23,614
+1,137
+5% +$100K 0.04% 197
2020
Q1
$1.71M Sell
22,477
-2,131
-9% -$182K 0.04% 181
2019
Q4
$2.18M Buy
24,608
+312
+1% +$25.9K 0.05% 182
2019
Q3
$1.84M Sell
24,296
-3,463
-12% -$237K 0.04% 188
2019
Q2
$2.02M Sell
27,759
-292
-1% -$23K 0.04% 184
2019
Q1
$2.26M Sell
28,051
-454,415
-94% -$37.2M 0.05% 179
2018
Q4
$44.5M Sell
482,466
-965
-0.2% -$84.9K 1.2% 21
2018
Q3
$45.7M Sell
483,431
-63,593
-12% -$6.03M 1.16% 19
2018
Q2
$50.7M Buy
547,024
+247,387
+83% +$24.2M 1.46% 11
2018
Q1
$28.4M Sell
299,637
-287,218
-49% -$31.6M 0.89% 34
2017
Q4
$56.8M Buy
586,855
+93
+0% +$8.77K 1.74% 7
2017
Q3
$52.1M Buy
586,762
+31,056
+6% +$2.36M 1.76% 8
2017
Q2
$40.3M Buy
555,706
+89,355
+19% +$6.01M 1.57% 6
2017
Q1
$30.4M Buy
466,351
+251,803
+117% +$15.8M 1.35% 11
2016
Q4
$13.4M Sell
214,548
-14,011
-6% -$855K 0.7% 43
2016
Q3
$14.4M Buy
228,559
+74,934
+49% +$4.85M 0.83% 32
2016
Q2
$9.51M Buy
153,625
+143,446
+1,409% +$8.74M 0.62% 57
2016
Q1
$581K Sell
10,179
-9,369
-48% -$522K 0.05% 214
2015
Q4
$1.16M Sell
19,548
-99,486
-84% -$5.73M 0.09% 162
2015
Q3
$6.48M Sell
119,034
-41,601
-26% -$2.71M 0.58% 54
2015
Q2
$10.8M Buy
160,635
+70,722
+79% +$4.62M 0.99% 25
2015
Q1
$5.26M Sell
89,913
-65,496
-42% -$3.96M 0.48% 64
2014
Q4
$10.2M Buy
155,409
+12,863
+9% +$811K 0.93% 27
2014
Q3
$8.23M Buy
142,546
+2,512
+2% +$139K 0.71% 33
2014
Q2
$7.9M Buy
140,034
+2,367
+2% +$124K 0.66% 45
2014
Q1
$7.08M Sell
137,667
-52,277
-28% -$2.64M 0.61% 48
2013
Q4
$10M Buy
189,944
+7,424
+4% +$365K 0.83% 21
2013
Q3
$8.16M Buy
182,520
+12,598
+7% +$558K 0.65% 34
2013
Q2
$7.03M Buy
+169,922
New +$7.43M 0.65% 33

Other funds holding ABBV

Clark Capital Management Group's ABBV Position: Q1 2026 in Review

Clark Capital Management Group reduced its AbbVie (ABBV) stake by 21% in Q1 2026, selling an estimated $28.5M and leaving 474,417 shares worth $103M. The position accounts for 0.64% of the portfolio, ranked #33.

Clark Capital Management Group first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $161M in Q3 2025. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Clark Capital Management Group held 474,417 shares of AbbVie worth $103M as of Q1 2026.
  • Clark Capital Management Group sold 128,376 AbbVie shares in Q1 2026, an estimated $28.5M.
  • AbbVie made up 0.64% of Clark Capital Management Group's portfolio in Q1 2026, its #33 holding.
  • Clark Capital Management Group first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
  • Clark Capital Management Group's AbbVie position peaked at $161M in Q3 2025.
  • 4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Clark Capital Management Group's 13F filing for Q1 2026, filed 15 May 2026.